San Diego, CA – January 3, 2023 – Mabwell Therapeutics, a U.S.-based biotechnology company, announced that China’s National Medical Products Administration (NMPA) has formally approved the Investigational New Drug (IND) application for MWTX-003 (9MW3011) injection. The approval enables Mabwell to initiate clinical trials for two indications: iron overload in patients with β-thalassemia and polycythemia vera.
MWTX-003 is a novel monoclonal antibody targeting TMPRSS6 (Transmembrane Serine Protease 6) to control iron homeostasis. By upregulating hepcidin expression in hepatocytes, it reduces iron absorption and release, effectively lowering serum iron levels. Preclinical studies have shown robust efficacy and durable iron suppression in disease models of both β-thalassemia and polycythemia vera.
With its novel mechanism and the high unmet medical need for rare hematologic disorders such as β-thalassemia and polycythemia vera, MWTX-003 is positioned as a potential first-in-class antibody therapy for rare blood diseases associated with dysregulated iron metabolism.
About Mabwell Therapeutics
Mabwell Therapeutics is a U.S.-based biotechnology company focused on developing innovative antibody-based therapies for serious and rare diseases. It is a wholly owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH).